Anti-cancer drug discovery and development

References

• Wong RS. Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research. CR (East Lansing, Mich) 2011; 30:87
   Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25:4798 - 811; http://dx.doi.org/10.1038/sj.onc.1209608; PMID: 16892092
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47 - 59; http://dx.doi.org/10.1038/nrm2308; PMID: 18097445
   PubMed Web of Science ®Google Scholar
• Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27:Suppl 1 S128 - 36; http://dx.doi.org/10.1038/onc.2009.50; PMID: 19641498
   PubMedGoogle Scholar
• Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27:Suppl 1 S149 - 57; http://dx.doi.org/10.1038/onc.2009.52; PMID: 19641500
   PubMedGoogle Scholar
• Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18:1414 - 24; http://dx.doi.org/10.1038/cdd.2011.17; PMID: 21415859
   PubMed Web of Science ®Google Scholar
• Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20:1397 - 411; http://dx.doi.org/10.1517/13543784.2011.609167; PMID: 21851287
   PubMed Web of Science ®Google Scholar
• Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66:4991 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-05-4254; PMID: 16707418
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 2010; 116:3197 - 207; http://dx.doi.org/10.1182/blood-2010-04-281071; PMID: 20631380
   PubMed Web of Science ®Google Scholar
• Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302:1036 - 8; http://dx.doi.org/10.1126/science.1090072; PMID: 14500851
   PubMed Web of Science ®Google Scholar
• Grillot DA, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996; 183:381 - 91; http://dx.doi.org/10.1084/jem.183.2.381; PMID: 8627151
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34:837 - 42; http://dx.doi.org/10.1016/j.leukres.2010.03.011; PMID: 20359747
   PubMed Web of Science ®Google Scholar
• Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88:386 - 401; PMID: 8695785
   PubMed Web of Science ®Google Scholar
• Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 1987; 316:79 - 84; http://dx.doi.org/10.1056/NEJM198701083160204; PMID: 3537802
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997; 41:501 - 32; http://dx.doi.org/10.1016/S1054-3589(08)61070-4; PMID: 9204157
   PubMedGoogle Scholar
• Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60:23 - 32; http://dx.doi.org/10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5; PMID: 8825412
   PubMed Web of Science ®Google Scholar
• Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13:115 - 23; http://dx.doi.org/10.1016/S1044-579X(02)00129-3; PMID: 12654255
   PubMed Web of Science ®Google Scholar
• Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, et al. Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 2001; 68:1207 - 14; http://dx.doi.org/10.1016/S0024-3205(00)01020-1; PMID: 11228105
   PubMed Web of Science ®Google Scholar
• Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278:20453 - 6; http://dx.doi.org/10.1074/jbc.C300138200; PMID: 12702731
   PubMed Web of Science ®Google Scholar
• Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13:1419 - 21; http://dx.doi.org/10.1038/sj.cdd.4401937; PMID: 16645636
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677 - 81; http://dx.doi.org/10.1038/nature03579; PMID: 15902208
   PubMed Web of Science ®Google Scholar
• Shore GC, Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am Soc Hematol Educ Program 2005; •••:226 - 30; http://dx.doi.org/10.1182/asheducation-2005.1.226; PMID: 16304385
   PubMedGoogle Scholar
• Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012; 287:10224 - 35; http://dx.doi.org/10.1074/jbc.M111.334532; PMID: 22311987
   PubMed Web of Science ®Google Scholar
• Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381:335 - 41; http://dx.doi.org/10.1038/381335a0; PMID: 8692274
   PubMed Web of Science ®Google Scholar
• Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275:983 - 6; http://dx.doi.org/10.1126/science.275.5302.983; PMID: 9020082
   PubMed Web of Science ®Google Scholar
• Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000; 97:7124 - 9; http://dx.doi.org/10.1073/pnas.97.13.7124; PMID: 10860979
   PubMed Web of Science ®Google Scholar
• Zhang H, Nimmer P, Rosenberg SH, Ng SC, Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem 2002; 307:70 - 5; http://dx.doi.org/10.1016/S0003-2697(02)00028-3; PMID: 12137781
   PubMed Web of Science ®Google Scholar
• Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46:4259 - 64; http://dx.doi.org/10.1021/jm030190z; PMID: 13678404
   PubMed Web of Science ®Google Scholar
• Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3:173 - 82; http://dx.doi.org/10.1038/35055085; PMID: 11175750
   PubMed Web of Science ®Google Scholar
• Zheng CH, Yang H, Zhang M, Lu SH, Shi D, Wang J, et al. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity. Bioorg Med Chem Lett 2012; 22:39 - 44; http://dx.doi.org/10.1016/j.bmcl.2011.11.101; PMID: 22172701
   PubMed Web of Science ®Google Scholar
• Zhou H, Chen J, Meagher JL, Yang CY, Aguilar A, Liu L, et al. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. J Med Chem 2012; 55:4664 - 82; http://dx.doi.org/10.1021/jm300178u; PMID: 22448988
   PubMed Web of Science ®Google Scholar
• Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, et al. The BH3 α-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem 2011; 286:9382 - 92; http://dx.doi.org/10.1074/jbc.M110.203638; PMID: 21148306
   PubMed Web of Science ®Google Scholar
• Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010; 53:4166 - 76; http://dx.doi.org/10.1021/jm1001265; PMID: 20443627
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-5836; PMID: 18451170
   PubMed Web of Science ®Google Scholar
• Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004; 11:389 - 95; http://dx.doi.org/10.1016/j.chembiol.2004.02.020; PMID: 15123268
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 2008; 7:1418 - 26; http://dx.doi.org/10.4161/cbt.7.9.6430; PMID: 18769131
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375 - 88; http://dx.doi.org/10.1016/j.ccr.2006.10.006; PMID: 17097560
   PubMed Web of Science ®Google Scholar
• Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006; 66:8731 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-06-0367; PMID: 16951189
   PubMed Web of Science ®Google Scholar
• Hughes CC, Prieto-Davo A, Jensen PR, Fenical W. The marinopyrroles, antibiotics of an unprecedented structure class from a marine Streptomyces sp. Org Lett 2008; 10:629 - 31; http://dx.doi.org/10.1021/ol702952n; PMID: 18205372
   PubMed Web of Science ®Google Scholar
• Hughes CC, Yang YL, Liu WT, Dorrestein PC, La Clair JJ, Fenical W. Marinopyrrole A target elucidation by acyl dye transfer. J Am Chem Soc 2009; 131:12094 - 6; http://dx.doi.org/10.1021/ja903149u; PMID: 19673475
   PubMed Web of Science ®Google Scholar
• Puthalakath H, Villunger A, O’Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293:1829 - 32; http://dx.doi.org/10.1126/science.1062257; PMID: 11546872
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, et al. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 2007; 104:3787 - 92; http://dx.doi.org/10.1073/pnas.0700115104; PMID: 17360431
   PubMed Web of Science ®Google Scholar
• Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15:3172 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-08-2985; PMID: 19366825
   PubMed Web of Science ®Google Scholar
• Schimmer AD, O’Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:8295 - 301; http://dx.doi.org/10.1158/1078-0432.CCR-08-0999; PMID: 19088047
   PubMed Web of Science ®Google Scholar
• Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16:1030 - 9; http://dx.doi.org/10.1038/cdd.2009.48; PMID: 19390557
   PubMed Web of Science ®Google Scholar
• Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One 2010; 5:e9924; http://dx.doi.org/10.1371/journal.pone.0009924; PMID: 20360986
   PubMed Web of Science ®Google Scholar
• Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res 2007; 17:839 - 49; http://dx.doi.org/10.1038/cr.2007.78; PMID: 17893711
   PubMed Web of Science ®Google Scholar
• Malik SA, Shen S, Mariño G, BenYounès A, Maiuri MC, Kroemer G. BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades. Autophagy 2011; 7:914 - 6; http://dx.doi.org/10.4161/auto.7.8.15785; PMID: 21508685
   PubMed Web of Science ®Google Scholar
• Gao P, Bauvy C, Souquère S, Tonelli G, Liu L, Zhu Y, et al. The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 2010; 285:25570 - 81; http://dx.doi.org/10.1074/jbc.M110.118125; PMID: 20529838
   PubMed Web of Science ®Google Scholar
• Lian J, Karnak D, Xu L. The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy 2010; 6:1201 - 3; http://dx.doi.org/10.4161/auto.6.8.13549; PMID: 20930561
   PubMed Web of Science ®Google Scholar
• Lian J, Wu X, He F, Karnak D, Tang W, Meng Y, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 2011; 18:60 - 71; http://dx.doi.org/10.1038/cdd.2010.74; PMID: 20577262
   PubMed Web of Science ®Google Scholar
• McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O’Hagan B, et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis 2010; 1:e108; http://dx.doi.org/10.1038/cddis.2010.86; PMID: 21368880
   PubMed Web of Science ®Google Scholar
• Ko CH, Shen SC, Yang LY, Lin CW, Chen YC. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells. Int J Cancer 2007; 121:1670 - 9; http://dx.doi.org/10.1002/ijc.22910; PMID: 17597109
   PubMed Web of Science ®Google Scholar
• Díaz de Greñu B, Iglesias Hernández P, Espona M, Quiñonero D, Light ME, Torroba T, et al. Synthetic prodiginine obatoclax (GX15-070) and related analogues: anion binding, transmembrane transport, and cytotoxicity properties. Chemistry 2011; 17:14074 - 83; http://dx.doi.org/10.1002/chem.201101547; PMID: 22069220
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu H, Tian Z, Griffith BN, Ji M, Li QQ. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci 2007; 80:767 - 74; http://dx.doi.org/10.1016/j.lfs.2006.11.004; PMID: 17156797
   PubMed Web of Science ®Google Scholar
• Hu ZY, Wang J, Cheng G, Zhu XF, Huang P, Yang D, et al. Apogossypolone targets mitochondria and light enhances its anticancer activity by stimulating generation of singlet oxygen and reactive oxygen species. Chin J Cancer 2011; 30:41 - 53; http://dx.doi.org/10.5732/cjc.010.10295; PMID: 21192843
   PubMedGoogle Scholar
• Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther 2011; 10:2373 - 83; http://dx.doi.org/10.1158/1535-7163.MCT-11-0326; PMID: 22006676
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26:2374 - 80; http://dx.doi.org/10.1038/sj.onc.1210028; PMID: 17016430
   PubMed Web of Science ®Google Scholar
• Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009; 76:327 - 41; http://dx.doi.org/10.1124/mol.109.056309; PMID: 19483105
   PubMed Web of Science ®Google Scholar
• Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, Longley DB, Fennell DA. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis: an international journal on programmed cell death 2011; 16:311-20.
   Google Scholar
• Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C, et al. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012; 287:68 - 80; http://dx.doi.org/10.1074/jbc.M111.271205; PMID: 22052903
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113:149 - 53; http://dx.doi.org/10.1182/blood-2008-02-138560; PMID: 18836097
   PubMed Web of Science ®Google Scholar
• Lieber J, Ellerkamp V, Wenz J, Kirchner B, Warmann SW, Fuchs J, et al. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr Surg Int 2012; 28:149 - 59; http://dx.doi.org/10.1007/s00383-011-2988-z; PMID: 21971946
   PubMed Web of Science ®Google Scholar
• Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27:6646 - 56; http://dx.doi.org/10.1038/onc.2008.259; PMID: 18663354
   PubMed Web of Science ®Google Scholar
• Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, Lee CT. -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacological research: the official journal of the Italian Pharmacological Society 2008; 58:323-31.
   Google Scholar
• Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008; 111:5350 - 8; http://dx.doi.org/10.1182/blood-2007-12-129833; PMID: 18292288
   PubMed Web of Science ®Google Scholar
• Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, et al. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 2009; 4:47; http://dx.doi.org/10.1186/1748-717X-4-47; PMID: 19852810
   PubMed Web of Science ®Google Scholar
• Moretti L, Li B, Kim KW, Chen H, Lu B. AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol 2010; 5:680 - 7; PMID: 20354451
   PubMed Web of Science ®Google Scholar
• Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010; 293:167 - 74; http://dx.doi.org/10.1016/j.canlet.2010.01.006; PMID: 20153924
   PubMed Web of Science ®Google Scholar
• Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 2011; 153:599 - 611; http://dx.doi.org/10.1111/j.1365-2141.2011.08669.x; PMID: 21492126
   PubMed Web of Science ®Google Scholar
• Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 2011; 10:1264 - 75; http://dx.doi.org/10.1158/1535-7163.MCT-10-1091; PMID: 21566062
   PubMed Web of Science ®Google Scholar
• Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008; 118:3651 - 9; http://dx.doi.org/10.1172/JCI35437; PMID: 18949058
   PubMed Web of Science ®Google Scholar
• Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS medicine 2007; 4:1681-89; discussion 90.
   Google Scholar
• Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008; 73:1632 - 42; http://dx.doi.org/10.1124/mol.107.044636; PMID: 18326051
   PubMed Web of Science ®Google Scholar
• Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 2007; 17:465 - 9; PMID: 17203189
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000; 97:4227 - 32; http://dx.doi.org/10.1073/pnas.97.8.4227; PMID: 10760290
   PubMed Web of Science ®Google Scholar
• Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7:4220 - 9; PMID: 11751523
   PubMed Web of Science ®Google Scholar
• Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol 2009; 182:7482 - 9; http://dx.doi.org/10.4049/jimmunol.0802813; PMID: 19494271
   PubMed Web of Science ®Google Scholar
• Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci U S A 2010; 107:10967 - 71; http://dx.doi.org/10.1073/pnas.1005256107; PMID: 20534453
   PubMed Web of Science ®Google Scholar
• Cippà PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, et al. Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. Cell Death Dis 2012; 3:e299; http://dx.doi.org/10.1038/cddis.2012.38; PMID: 22513873
   PubMedGoogle Scholar
• Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. J Immunol 2010; 185:2555 - 62; http://dx.doi.org/10.4049/jimmunol.0903656; PMID: 20639495
   PubMed Web of Science ®Google Scholar
• Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, et al. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res 2012; 72:2565 - 77; http://dx.doi.org/10.1158/0008-5472.CAN-11-3603; PMID: 22589275
   PubMed Web of Science ®Google Scholar
• Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119:5807 - 16; http://dx.doi.org/10.1182/blood-2011-12-400929; PMID: 22538851
   PubMed Web of Science ®Google Scholar
• Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther 2010; 9:2943 - 50; http://dx.doi.org/10.1158/1535-7163.MCT-10-0427; PMID: 20829195
   PubMed Web of Science ®Google Scholar
• Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010; 9:545 - 57; http://dx.doi.org/10.1158/1535-7163.MCT-09-0651; PMID: 20179162
   PubMed Web of Science ®Google Scholar
• Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007; 121:2387 - 94; http://dx.doi.org/10.1002/ijc.22977; PMID: 17688235
   PubMed Web of Science ®Google Scholar
• Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118:3579 - 90; http://dx.doi.org/10.1182/blood-2011-03-340364; PMID: 21772052
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118:3901 - 10; http://dx.doi.org/10.1182/blood-2010-11-317438; PMID: 21835956
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 2011; 17:5973 - 81; http://dx.doi.org/10.1158/1078-0432.CCR-11-0955; PMID: 21821698
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115:3304 - 13; http://dx.doi.org/10.1182/blood-2009-07-233304; PMID: 20197552
   PubMed Web of Science ®Google Scholar
• Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 2009; 4:e6651; http://dx.doi.org/10.1371/journal.pone.0006651; PMID: 19684859
   PubMed Web of Science ®Google Scholar
• Weber A, Kirejczyk Z, Potthoff S, Ploner C, Hacker G. Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. Translational oncology 2009; 2:73-83.
   Google Scholar
• Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, et al. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 2012; 18:783 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-11-1166; PMID: 22173547
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang X, Lentz C, Abi-Daoud M, Paré GC, Yang X, et al. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol 2011; 179:2162 - 8; http://dx.doi.org/10.1016/j.ajpath.2011.07.010; PMID: 21893020
   PubMed Web of Science ®Google Scholar
• Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 2008; 7:2339 - 47; http://dx.doi.org/10.1158/1535-7163.MCT-08-0285; PMID: 18723481
   PubMed Web of Science ®Google Scholar
• Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 2009; 11:945 - 55; PMID: 19724688
   PubMed Web of Science ®Google Scholar
• Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007; 104:19512 - 7; http://dx.doi.org/10.1073/pnas.0709443104; PMID: 18040043
   PubMed Web of Science ®Google Scholar
• Fassl A, Tagscherer KE, Richter J, Berriel Diaz M, Alcantara Llaguno SR, Campos B, et al. Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene 2012; http://dx.doi.org/10.1038/onc.2011.615; PMID: 22249262
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Perkins G. Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis. Cell Death Dis 2011; 2:e227; http://dx.doi.org/10.1038/cddis.2011.109; PMID: 22071632
   PubMed Web of Science ®Google Scholar
• Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res 2012; 72:3069 - 79; http://dx.doi.org/10.1158/0008-5472.CAN-11-4106; PMID: 22525702
   PubMed Web of Science ®Google Scholar
• Zall H, Weber A, Besch R, Zantl N, Häcker G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 2010; 9:164; http://dx.doi.org/10.1186/1476-4598-9-164; PMID: 20576107
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13:621 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-06-1526; PMID: 17255285
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008; 140:181 - 90; PMID: 18028486
   PubMed Web of Science ®Google Scholar
• Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:1181 - 9; http://dx.doi.org/10.1002/pbc.21433; PMID: 18085673
   PubMed Web of Science ®Google Scholar
• Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 2007; 9:1030 - 7; http://dx.doi.org/10.1593/neo.07778; PMID: 18084610
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Huang XF, Mu SJ, An QX, Xia AJ, Chen R, et al. Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl 2010; 12:390 - 9; http://dx.doi.org/10.1038/aja.2009.87; PMID: 20081872
   PubMed Web of Science ®Google Scholar
• Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7:2192 - 202; http://dx.doi.org/10.1158/1535-7163.MCT-08-0333; PMID: 18645028
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther 2012; 11:1122 - 32; http://dx.doi.org/10.1158/1535-7163.MCT-12-0021; PMID: 22411899
   PubMed Web of Science ®Google Scholar
• Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010; 10:903 - 17; http://dx.doi.org/10.4161/cbt.10.9.13273; PMID: 20855960
   PubMed Web of Science ®Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149 - 59; http://dx.doi.org/10.1016/S1470-2045(10)70261-8; PMID: 21094089
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012; 30:488-96.
   Google Scholar
• Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18:3163 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-11-3090; PMID: 22496272
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. U.S. National Institute of Health.
   Google Scholar
• Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14:943 - 51; PMID: 17205078
   PubMed Web of Science ®Google Scholar
• Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118:1663 - 74; http://dx.doi.org/10.1182/blood-2011-04-347849; PMID: 21673344
   PubMed Web of Science ®Google Scholar
• Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29:909-16.
   Google Scholar
• Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2012.
   Google Scholar
• Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010; 5:1637 - 43; http://dx.doi.org/10.1097/JTO.0b013e3181e8f4dc; PMID: 20808253
   PubMed Web of Science ®Google Scholar
• Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 2011; 6:781 - 5; http://dx.doi.org/10.1097/JTO.0b013e31820a0ea6; PMID: 21289522
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, et al, Mayo Phase 2 Consortium, California Consortium. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011; 6:1757 - 60; http://dx.doi.org/10.1097/JTO.0b013e31822e2941; PMID: 21918390
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299 - 305; http://dx.doi.org/10.1182/blood-2008-02-137943; PMID: 18931344
   PubMed Web of Science ®Google Scholar
• Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16:4038 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-10-0822; PMID: 20538761
   PubMed Web of Science ®Google Scholar
• Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, et al. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 2012; 119:2171 - 2; http://dx.doi.org/10.1182/blood-2011-11-391037; PMID: 22383790
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010; 66:1079 - 85; http://dx.doi.org/10.1007/s00280-010-1265-5; PMID: 20165849
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer 2012; 106:839 - 45; http://dx.doi.org/10.1038/bjc.2012.21; PMID: 22333598
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011; 74:481 - 5; http://dx.doi.org/10.1016/j.lungcan.2011.05.005; PMID: 21620511
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 2010; 10:285 - 9; http://dx.doi.org/10.3816/CLML.2010.n.059; PMID: 20709666
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu G, Gao J, Song T. Inclusion complex of a Bcl-2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity. Mol Pharm 2010; 7:1348 - 54; http://dx.doi.org/10.1021/mp100081x; PMID: 20550194
   PubMed Web of Science ®Google Scholar
• Imai A, Zeitlin BD, Visioli F, Dong Z, Zhang Z, Krishnamurthy S, et al. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res 2012; 72:716 - 25; http://dx.doi.org/10.1158/0008-5472.CAN-10-2873; PMID: 22158856
   PubMed Web of Science ®Google Scholar
• Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, et al. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 78:879 - 87; http://dx.doi.org/10.1016/j.ijrobp.2010.04.024; PMID: 20675079
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2003; 17:2036 - 45; http://dx.doi.org/10.1038/sj.leu.2403109
   PubMed Web of Science ®Google Scholar
• Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A 2011; 108:8785 - 90; http://dx.doi.org/10.1073/pnas.1100769108; PMID: 21555592
   PubMed Web of Science ®Google Scholar
• Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26:120 - 5; http://dx.doi.org/10.1101/gad.182980.111; PMID: 22279045
   PubMed Web of Science ®Google Scholar
• Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 2009; 8:2084 - 96; http://dx.doi.org/10.4161/cbt.8.21.9895; PMID: 19823038
   PubMed Web of Science ®Google Scholar
• Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, et al. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol Pharmacol 2012; 81:748 - 58; http://dx.doi.org/10.1124/mol.112.077586; PMID: 22357666
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899 - 905; http://dx.doi.org/10.1038/nature08822; PMID: 20164920
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 2012; 72:757 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-11-2781; PMID: 22147262
   PubMed Web of Science ®Google Scholar